8-K: NovaBay Pharmaceuticals Completes Sale of Eyecare Business, Adjourns Meeting on Dissolution Vote

NovaBay Pharmaceuticals has finalized the sale of its Avenova eyecare business for $11.5 million and has adjourned its special stockholder meeting to allow more time for voting on the company's planned liquidation.

Summary

• NovaBay Pharmaceuticals completed the sale of its Avenova eyecare business to PRN Physician Recommended Nutriceuticals, LLC for $11.5 million.
• The sale included substantially all of NovaBay's revenue-generating and operating assets.
• A portion of the sale proceeds, $500,000, was placed in escrow for potential indemnification obligations or working capital adjustments.
• The company also discharged a $507,953.72 bridge loan as part of the transaction.
• The sale was approved by stockholders at a special meeting, which was adjourned multiple times to secure sufficient votes.
• The company is now seeking stockholder approval for a plan of complete liquidation and dissolution.
• A special meeting has been adjourned until January 30, 2025, to allow additional time for stockholders to vote on the liquidation proposal.
• Approximately 49% of outstanding shares have voted in favor of the liquidation, but over 50% is required for approval.
• The company believes liquidation provides the best opportunity to optimize value for stockholders.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company selling its core business and planning to liquidate. While the sale provides some value, the overall outlook is not positive for the company's future.

Positives

• The sale of the Avenova business provides $11.5 million in cash proceeds.
• The company has discharged a $507,953.72 bridge loan.
• Management believes the liquidation plan will optimize value for stockholders.
• A transition services agreement ensures a smooth handover of the business to PRN.
• The Avenova brand is expected to thrive under new ownership.

Negatives

• The company is planning to liquidate and dissolve, indicating the end of its operations.
• The liquidation plan requires stockholder approval, which is not yet secured.
• The special meeting has been adjourned multiple times due to insufficient votes.
• The company's revenue-generating assets have been sold, leaving it with no operating business.

Risks

• The liquidation plan is subject to stockholder approval, which is not guaranteed.
• The final amount of proceeds from the sale is subject to working capital adjustments.
• The company's future is dependent on the successful execution of the liquidation plan.
• There is a risk that the company may not be able to optimize value for stockholders through liquidation.
• The company has no remaining operating business after the sale of Avenova.

Future Outlook

The company plans to liquidate and dissolve after receiving stockholder approval, with the goal of optimizing value for stockholders. The company will continue to solicit votes for the liquidation proposal until the reconvened meeting on January 30, 2025.

Management Comments

• The divestiture of our eyecare business has allowed us to monetize this valuable asset and to return value to our stockholders, while providing the Avenova brand an opportunity to grow, flourish and reach its full potential in the future, said Justin Hall, NovaBay CEO.
• This transaction brings significant change to NovaBay, ending one chapter and creating an exciting new opportunity for the Avenova brand.
• We will be excited to see the brand thrive in the years to come.
• We appreciate the support of our stockholders in approving this transaction.

Industry Context

The sale of NovaBay's eyecare business reflects a strategic shift for the company, moving away from its core operations and towards a planned liquidation. This type of transaction is not uncommon for companies facing financial challenges or seeking to maximize shareholder value through asset sales.

Comparison to Industry Standards

• The sale of the Avenova business for $11.5 million is a significant transaction for a company of NovaBay's size.
• The decision to liquidate and dissolve the company is a drastic measure, indicating a lack of confidence in the company's future as a going concern.
• The use of an escrow account for working capital adjustments is a standard practice in asset sale transactions.
• The transition services agreement is a common mechanism to ensure a smooth handover of operations to the buyer.
• The consultancy agreement with the CFO is a way to retain expertise during the transition period.

Stakeholder Impact

• Shareholders will receive proceeds from the sale and liquidation.
• Employees will likely be impacted by the sale and liquidation of the company.
• Customers of Avenova will now be served by PRN.
• Suppliers and creditors will be impacted by the liquidation of the company.

Next Steps

• Stockholders will vote on the liquidation proposal at the reconvened special meeting on January 30, 2025.
• The company will continue to solicit votes for the liquidation proposal.
• The company will provide transition services to PRN for four months.
• The company will distribute proceeds to stockholders and others in connection with the liquidation.

Key Dates

Keywords

Avenova, Asset Sale, Liquidation, Dissolution, PRN, Eyecare, Stockholders, Special Meeting, Bridge Loan, Working Capital